Lactic acid bacterial strain, composition for improving gut microbiota composition, and product and application of said lactic acid bacterial strain

Pediococcus acidilactici extracellular vesicles address the limitations of current gastrointestinal flora regulation by enhancing beneficial bacterial growth and restoring intestinal balance, providing a safer and more effective oral intervention for improving microbial composition.

JP2024163005AActive Publication Date: 2024-11-21SUNWAY BIOTECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024012979
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-08
Filing Date
2024-01-31
Publication Date
2024-11-21
Estimated Expiration
2044-01-31

AI Technical Summary

Technical Problem

Current methods for regulating and controlling gastrointestinal flora, such as probiotics and fecal microbiota transplantation, face limitations including the inability to form colonies, susceptibility to bile salts, and safety concerns, particularly with drug-resistant genes in fecal flora, necessitating improved and safer interventions.

Method used

A novel composition comprising extracellular vesicles secreted from Pediococcus acidilactici, deposited as NCIMB 44102, which influences the growth of specific bacterial species and improves intestinal microbial species composition, including Firmicutes and Bacteroidetes, and is administered orally for effective regulation.

Benefits of technology

The extracellular vesicles from Pediococcus acidilactici enhance the abundance of beneficial bacteria, restore intestinal microbial balance, and promote a healthy microbial composition, particularly in Alzheimer's disease models, offering a safer and more effective alternative to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163005000001_ABST
    Figure 2024163005000001_ABST
Patent Text Reader

Abstract

To provide a lactic acid bacterial strain and a composition for improving a gut microbiota composition, and a product and an application of the lactic acid bacterial strain.SOLUTION: The primary object of the present invention is to provide a lactic acid bacterial strain and a composition for improving a gut microbiota composition, where the composition comprises the lactic acid bacterial strain and / or extracellular vesicles secreted by the lactic acid bacterial strain. Another objective of the present invention is to provide an application of the lactic acid bacterial strain to prepare the composition for improving the gut microbiota composition, and a product of the lactic acid bacterial strain. The composition of the present invention has the capability to influence the growth of Firmicutes and Bacteroidetes, thereby improving the gut microbiota composition.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the technical field of improving intestinal microbial species composition, and in particular to the technical field of a composition for improving intestinal microbial species composition comprising a novel lactic acid bacterium and / or its secreted extracellular vesicles. [Background technology]

[0002] The composition and changes of intestinal microbes are related to human health. A complex nervous system is distributed in the intestinal tract, and the intestinal tract and the brain communicate and influence each other via the gut-brain axis. Intestinal microbes produce metabolites and other brain neurotransmitters that affect intestinal cells and immune cells, thereby affecting the host's gastrointestinal function, and ultimately its behavior and emotional expression.

[0003] Intestinal microorganisms include various symbiotic microorganisms, which are mainly composed of bacteria, most of which are obligate anaerobes, and are mainly divided into four phyla: Bacteroidetes, Firmicutes, Actinobacteria, and Proteobacteria. In addition, research has found that the composition ratio of Bacteroidetes and Firmicutes varies depending on the disease, and the intestinal flora of healthy people contains a large amount of Bacteroidetes, while the intestinal flora of patients suffering from disease contains a large amount of Firmicutes. In the intestines of obese patients, the Bacteroidetes phylum is greatly reduced, including a reduction in many intestinal probiotics, and the abundance of Bacteroides thetaiotaomicron is relatively low in the intestines of obese patients, and a relationship with obesity-related metabolites and hormonal changes has been suggested, so there is a high possibility of identifying key microorganisms related to the disease and using them as targeted treatments. At the same time, gut microbes play an important role in maintaining the stability of the intestinal tract and the integrity of the mucosal immune system, and gut microbes are thought to help maintain intestinal health and regulate the permeability of the intestinal barrier. Furthermore, evidence has already been established that proves that reduced and altered microbial diversity is associated with numerous diseases and functional disorders, such as obesity, inflammatory bowel disease (IBD), autism, and neurodegenerative diseases, and specific gut microbes may change with the progression of the disease to different degrees (see Non-Patent Documents 1 to 4).

[0004] Nowadays, gastrointestinal flora is usually regulated and controlled by taking probiotics directly. Probiotics have the positive effect of increasing good (beneficial) bacteria and suppressing bad (harmful) bacteria through colonization. Even now, fecal microbiota transplant (FMT) is used to transplant normal bacterial populations into the host's digestive system.

[0005] However, probiotics have limited impact on bacterial populations due to the universal problem of non-colonization, and FMT treatment still has many drawbacks and its safety remains controversial. At present, fecal microbiota transplantation mainly involves the upper, middle and lower gastrointestinal tract routes. In the case of the upper gastrointestinal tract route, fecal microbiota is orally administered, but the disadvantage is that the microorganisms are easily affected by bile salts. In the case of the middle gastrointestinal tract route, fecal microbiota can be administered by nasal tube or percutaneous endoscopic gastric tube, but the disadvantage is that if not administered properly, there is a risk of erroneous aspiration and reflux, and the microorganisms will also be affected by bile salts. In the case of the lower gastrointestinal tract route, fecal microbiota is administered by colonoscopy, enema or endoscopic enteral tube placement, but the disadvantage is that the fecal microbiota only covers the sigmoid colon, and fecal microbiota transplantation must be performed multiple times. In the past, FMT was recognized as one of the safe treatment methods, but according to the latest clinical reports and cases notified by the US Food and Drug Administration, a patient received fecal flora from a healthy donor, but the E. coli in the fecal flora already had many types of drug resistance genes, which posed a risk of death to the FMT recipient. In addition, current technology is still unable to effectively evaluate and determine the drug resistance genes in the flora of healthy bacterial donors for FMT, so FMT still has potential risks.

[0006] In view of the limitations and shortcomings of the current methods for regulating and controlling the gastrointestinal flora, and because the composition and changes of intestinal microorganisms are closely related to human health and many diseases, the inventors of the present application have longed for the use of nano-sized spherical lipid bilayers and extracellular vesicles (EVs) containing component structures such as nucleic acids and proteins, which can safely and effectively regulate and control the composition and changes of intestinal microorganisms by interacting with neighboring bacteria. In view of this, the inventors of the present application have diligently researched and invented, and have finally researched, developed and completed the novel lactic acid bacteria of the present invention, a composition for improving the composition of intestinal microbial species, and products and uses of the lactic acid bacteria, and have achieved the efficacy of effectively improving intestinal health by extracellular vesicles secreted from a small amount of microorganisms. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Liu et al. Nature Medicine 2017,23,859-868. [Non-Patent Document 2] Hall et al. Genome Medicine 2017,9,103. [Non-Patent Document 3] Finegold et al. Anaerobe 2010,16,444-453. [Non-Patent Document 4] Scheperjans et al. Movement Disorders 2015,30,350-358. Summary of the Invention [Problem to be solved by the invention]

[0008] The present invention has as its main object to provide a lactic acid bacterium and a composition for improving the composition of intestinal microbial species, the composition including the lactic acid bacterium and / or extracellular vesicles secreted by the lactic acid bacterium. In addition, the composition for improving the composition of intestinal microbial species may be provided as a composition for oral ingestion. [Means for solving the problem]

[0009] To achieve the above objectives, the present invention proposes a novel lactic acid bacterium, Pediococcus acidilactici, deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd), UK, under accession number NCIMB 44102.

[0010] Furthermore, the present invention provides a composition for improving intestinal microbial species composition, comprising an effective amount of extracellular vesicles, wherein the extracellular vesicles are capable of being secreted from a lactic acid bacterium, and the lactic acid bacterium is Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0011] The effective amount in the composition of the present invention is a particle number concentration of at least 10 8 The extracellular vesicles are particles / ml, and the extracellular vesicles are any one selected from the group consisting of exosomes, microvesicles, ectosomes, and apoptotic bodies.

[0012] In addition, the above-mentioned compositions of the present invention have the ability to improve the intestinal microbial species composition, which can affect the clinical course of Alzheimer's disease (AD).

[0013] Furthermore, such extracellular vesicles in the compositions of the present invention described above are capable of influencing the growth of Firmicutes and / or Bacteroidetes.

[0014] At the same time, such extracellular vesicles are also capable of influencing the growth of at least one bacterial class, and the bacterial class is at least one selected from the group consisting of Bacteroidia, Clostridia, and Bacilli.

[0015] The extracellular vesicles are also capable of influencing the growth of at least one bacterial family, the bacterial family being at least one selected from the group consisting of Lactobacillaceae, Muribaculaceae, Lachnospiraceae, Clostridiaceae, Desulfovibrionaceae, Erysipelotrichaceae, Eggerthellaceae, Akkermansiaceae, Ruminococcaceae, and Eubacteriaceae. The extracellular vesicles are also capable of influencing the growth of Muribaculum and / or Lachnospira.

[0016] Furthermore, in the composition of the present invention as described above, such extracellular vesicles are capable of promoting the growth of acidophilic Lactobacillus acidophilus.

[0017] In one embodiment, the present invention provides a nutritional supplement, comprising Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0018] In one embodiment, the present invention provides a food product, the food product comprising Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0019] In one embodiment, the present invention provides a dietary supplement comprising Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0020] In one embodiment, the present invention provides a food additive, comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0021] In one embodiment, the present invention provides a pharmaceutical composition comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0022] In one embodiment, the present invention provides a feed, the feed comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

[0023] Another object of the present invention is to provide a use of lactic acid bacteria for preparing a composition for improving intestinal microbial species composition, wherein the lactic acid bacteria is Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the UK under accession number NCIMB 44102. In addition, the present invention also provides a novel lactic acid bacterium and / or extracellular vesicles secreted therefrom for use in improving intestinal microbial species composition, wherein the lactic acid bacteria is Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the UK under accession number NCIMB 44102. Effect of the Invention

[0024] Another object of the present invention is to provide an application of a composition for improving intestinal microbial species composition, and this type of application includes product formats that are easy to use in daily life, such as foods, beverages, health foods, additives, and medical compositions, which are provided to the general public for consumption to maintain intestinal health on a daily basis. [Brief description of the drawings]

[0025] [Figure 1A] 1 is a photographic image of extracellular vesicles of the lactic acid bacteria of the present invention obtained by observation with a transmission electron microscope (TEM). [Figure 1B] FIG. 2 is a graph showing the average particle size distribution of extracellular vesicles of the lactic acid bacteria of the present invention. [Diagram 2]1 is a bar graph showing the relative abundance of microbial species in the intestines of mice after oral administration of the lactic acid bacteria extracellular vesicles of the present invention to APPNL-GF / NL-GF transgenic mice. [Figure 3A] 1 is a line graph showing the growth of a co-culture of extracellular vesicles of lactic acid bacteria of the present invention and acidophilic Lactobacillus acidophilus. [Figure 3B] 1 is a bar graph showing the growth of a co-culture of extracellular vesicles of lactic acid bacteria of the present invention and acidophilic lactobacilli. [Figure 4A] 1 is a line graph showing the growth of co-cultured extracellular vesicles of lactic acid bacteria of the present invention with enterobacteria (e.g., Lachnospira). [Figure 4B] 1 is a bar graph showing the growth of co-cultured extracellular vesicles of lactic acid bacteria of the present invention with enterobacteria (e.g., Lachnospira). [Figure 4C] 1 is a line graph showing the growth of a co-culture of extracellular vesicles of the lactic acid bacteria of the present invention with enteric bacteria (e.g., Ruminococcus). [Figure 4D] 1 is a bar graph showing the growth of a co-culture of extracellular vesicles of the lactic acid bacteria of the present invention with enteric bacteria (e.g., Ruminococcus). [Diagram 5] Fluorescent staining images showing the reaction between extracellular vesicles of the lactic acid bacteria of the present invention and mouse fecal microorganisms. [Figure 6A] FIG. 1 shows the results of a flow cell sorter analysis of intestinal microorganisms in mice to which extracellular vesicles of the lactic acid bacteria of the present invention had not been added. [Figure 6B] FIG. 1 shows the results of a flow cell sorter analysis of intestinal microorganisms in mice to which extracellular vesicles of the lactic acid bacteria of the present invention had been added. [Figure 7] 1 is a bar graph showing the relative abundance of intestinal microbial species in mice that ingested the lactic acid bacteria extracellular vesicles of the present invention. [Figure 8] This is a phylogenetic tree including Pediococcus acidilactici. [Figure 9] Electropherogram of the CGPA01_1590-F / R primer amplification product. [Figure 10]Electropherogram of the MA18 / 5M_850-F / R primer amplification product. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The details of the present invention will be explicitly described below using examples, but these examples are merely illustrative and not limiting, and the present invention is not limited to these examples. Unless otherwise specified, all materials used in the present invention are preferably commercially available and easily available, and the available routes shown below are merely examples.

[0027] The present invention provides a novel lactic acid bacterium and a composition for improving the intestinal microbial species composition, the composition comprising the lactic acid bacterium and / or its secreted extracellular vesicles, the lactic acid bacterium being Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the UK under the accession number NCIMB 44102. The inventors of the present application conducted an experiment using a transgenic mouse animal model of Alzheimer's disease (knock-in of the amyloid beta precursor protein gene (APP gene)) and found that the extracellular vesicles secreted from the Pediococcus acidilactici have a novel use and function for improving the intestinal microbial species composition.

[0028] In addition, the Pediococcus acidilactici of the present invention is a novel lactic acid bacteria isolate obtained by the inventor of the present application from the intestinal tract of chickens in the laboratory.

[0029] Through analysis of a mouse animal model, it has been found that the extracellular vesicles secreted from Pediococcus acidilactici of the present invention can effectively improve the abundance of intestinal microorganisms in mice, i.e., the extracellular vesicles can effectively improve the intestinal microbial species composition of transgenic mice with Alzheimer's disease, and can restore the intestinal microbial species composition of the transgenic mice to a microbial species composition similar to that under healthy conditions.

[0030] The above-mentioned lactic acid bacteria isolates, including their subculture progeny or mutant strains, still have the same bacterial species characteristics, genomics or uses (used to improve the intestinal microbial species composition) as those of the present invention.

[0031] The compositions herein may include, but are not limited to, application forms of the products applicable to the present invention, such as nutritional supplements, food products, dietary supplements, food additives, veterinary and human pharmaceutical compositions, feed, beverages, health foods, animal drinking water additives, animal feed additives, and beverage additives.

[0032] The term "improvement" means that a composition containing Pediococcus acidilactici and / or extracellular vesicles thereof of the present invention can effectively improve the intestinal microbial species composition compared to a composition not containing Pediococcus acidilactici and / or extracellular vesicles thereof.

[0033] The term "effective amount" means an effective amount of one or more active ingredients of enteric microbial species to effectively improve, treat or reverse a disease, also called a "therapeutically effective amount" or an "improving effective amount." Thus, the term "pharmaceutical acceptable" means that the substance or composition must be compatible with other ingredients of the formulation and is not harmful to the patient.

[0034] The composition of the present invention refers to a preparation of the above-mentioned Pediococcus acidilactici and / or its extracellular vesicles together with a pharma- ceutical or food acceptable carrier into a dosage form applicable to the composition of the present invention, using techniques well known to those skilled in the art, among which the dosage forms include, but are not limited to, a solution, an emulsion, a suspension, a powder, a tablet, a pill, an orally disintegrating tablet, a troche, a capsule, and other dosage forms similar to or applicable to the present invention.

[0035] In the above composition, one or more solubilizing agents, buffers, preservatives, colorants, fragrances, flavorings, excipients, and the like that are commonly used in the pharmaceutical field can also be appropriately added as necessary.

[0036] In another preferred embodiment, the aforementioned composition provided by the present invention can be further added into edible materials and prepared into food products or health products, wherein the edible materials are selected from the group consisting of water, fluid milk products, milk, concentrated milk, fermented milk, such as yogurt, frozen yogurt, sour milk, and lactic fermenting beverages, milk powder, ice cream, cream cheese, dry cheese, soybean milk, fermented soybean milk, fruit and vegetable juice, juice, sports drink, confectionery, jelly, baby food, health food, animal feed, and the like. This includes, but is not limited to, dietary supplements, herbal feed, and dietary supplements.

[0037] Furthermore, the present invention also provides a method for improving gut microbial species composition, which comprises providing an effective amount of the above-mentioned composition to a patient suffering from a gut disease or a patient with Alzheimer's disease, for improving the gut microbial species composition.

[0038] In addition, the present invention also provides a method or use for preparing a composition for improving intestinal microbial species composition comprising the above-mentioned Pediococcus acidilactici and / or its secreted extracellular vesicles.

[0039] The composition provided by the present invention and the method used to improve the intestinal microbial species composition thereof are not particularly limited in terms of the route of administration, so long as it is appropriately adjusted according to requirements, and a suitable route of administration includes oral administration suitable for an appropriate dosage form.

[0040] <Origin of the strain> The acidophilic lactobacillus (Lactobacillus acidophilus) used in the following examples of the present invention is a standard strain purchased from the Bioresource Collection and Research Center (BCRC) in Hsinchu, Taiwan: Lactobacillus acidophilus BCRC 14079. The Lachnospiraceae sp. and Ruminococcaceae sp. used in the present invention are standard strains purchased from the American Type Culture Collection (ATCC): Lachnospiraceae sp. TSD-26 and Ruminococcaceae sp. TSD-27, respectively. The novel lactic acid bacterium of the present invention is Pediococcus acidilactici, which was isolated in the laboratory from the intestinal tract of chickens and has been deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the UK under accession number NCIMB 44102.

[0041] <Animal breeds> The animal breeds used in the following examples of the present invention are APP1, an AD model using amyloid-β precursor protein gene knock-in. NL-G-F / NL-G-FThe transgenic mice (Transgenic:TG) had the Swedish mutant gene (KM670 / 671NL) and the Iberian mutant gene (I716F) introduced into their Aβ sequences to increase Aβ production and improve the Aβ42 / 40 ratio. In the transgenic mice, memory impairment first appeared at 6 months of age, and in the control group, C57BL / 6 (non-transgenic: non-TG) mice were used as controls (Reference 1: Nilsson et al. ACS Chemical Neuroscience 2014,5,499-502).

[0042] <Preparation of extracellular vesicles> First, the Pediococcus acidilactici of the present invention was cultured at 37°C for 24 hours using MRS medium, centrifuged at 10,000×g for 30 minutes to remove the bacterial cells, filtered the supernatant, and then the obtained filtrate was centrifuged at 247,537×g and 4°C at ultrahigh speed, after which the supernatant was removed. The precipitate was then washed with Dulbecco's phosphate buffered saline (DPBS), and the resulting washings were filtered through a 0.22μm bacteria-removing membrane, and then centrifuged again at 247,537×g and 4°C at ultrahigh speed, after which the supernatant was removed, and the precipitate was redissolved in DPBS to obtain extracellular vesicles, which were then stored at -80°C (Reference 2: Choi et al. Experimental Neurobiology 2019,28,158-171). EXAMPLES

[0043] <Example 1: Morphological characteristics of extracellular vesicles secreted from Pediococcus acidilactici of the present invention> In this embodiment, the Pediococcus acidilactici culture solution of the present invention is centrifuged by ultra-high speed centrifugation to purify the extracellular vesicles (LAB-EVs) and the morphological characteristics of the extracellular vesicles (LAB-EVs) obtained by purification are observed through a transmission electron microscope. As shown in FIG. 1A, the extracellular vesicles have a spherical lipid bilayer structure of nanometer size. In addition, the LAB-EVs can be analyzed using a nanoparticle tracking analyzer after being appropriately diluted with Dulbecco's phosphate buffered saline (DPBS). The diluted liquid is irradiated with a laser light source and the Brownian motion of the scattered light nanoparticles is observed through a microscope, so that the average particle size and particle number (quantitative) of the LAB-EV sample are calculated. FIG. 1B shows the average particle size distribution of the LAB-EVs, and the average particle size of the LAB-EVs is about 125 nanometers (nm). EXAMPLES

[0044] Example 2: Relative abundance of intestinal microbial species in transgenic mice after oral administration of extracellular vesicles of Pediococcus acidilactici of the present invention In this example, mice were given one dose of mouse extracellular vesicles (LAB-EVs) per day via oral administration, and after four weeks of feeding with mouse LAB-EVs, the mice were sacrificed and the relative abundance of microbial species in the mouse intestine was analyzed.

[0045] FIG. 2 shows the relative abundance of microbial species in the intestine of mice after oral administration of the Pediococcus acidilactici extracellular vesicles (LAB-EVs) of the present invention, in which non-TG Veh: represents oral administration of the solvent to non-transgenic mice (n=6), TG Veh: represents oral administration of the solvent to transgenic mice (Amyloid beta precursor protein gene (APP gene) knock-in) (n=6), and TG LAB-EV: represents oral administration of LAB-EV to transgenic mice (APP gene knock-in) (n=6). Here, Veh (Vehicle) is DPBS, the solvent for LAB-EVs.

[0046] Figure 2 shows the top 10 rankings of relative abundance of bacterial families in the mouse gut microbiota, and the families other than the top 10 are classified as others, among which the top 10 rankings include Lactobacillaceae, Muribaculaceae, Lachnospiraceae, Clostridiaceae, Desulfovibrionaceae, Erysipelotrichaceae, Eggerthellaceae, Akkermansiaceae, Ruminococcaceae, and Eubacteriaceae. In addition, as can be seen from the results in Figure 2, there are differences between the family classes of microorganisms in the intestines of non-TG Veh mice and TG Veh mice, and the intestinal microbial composition of TG LAB-EV mice is relatively similar to that of non-TG Veh mice, which means that the intestinal microbial species composition of transgenic mice is improved to a certain extent after the administration of LAB-EV, which also indicates that the intestinal microbial species composition of transgenic mice can be restored to a similar composition to that of normal mice. Therefore, LAB-EV can effectively improve the intestinal microbial species of transgenic mice, and restore the intestinal microbial species composition of mice to a microbial species composition similar to that under healthy conditions. EXAMPLES

[0047] <Example 3: Co-culture of extracellular vesicles of Pediococcus acidilactici of the present invention with acidophilic Lactobacillus acidophilus> In this example, LAB-EVs of the present invention were co-cultured with acidophilic lactobacilli to analyze whether they have the potential to promote the growth of acidophilic lactobacilli, as in vitro testing. After co-culture of LAB-EVs with acidophilic lactobacilli, the absorbance values ​​at a wavelength of 600 nm were measured at different time points, and finally, the line graphs and bar graphs shown in Figures 3A and 3B were obtained, respectively, in which the data from three replicates were expressed as mean ± standard error of the mean (SEM), and statistical analysis was performed using one-way analysis of variance, followed by multiple group comparison test with Tukey's test, and significant differences were marked with different English alphabets.

[0048] As can be seen from the results shown in Figures 3A and 3B, LAB-EV promotes the growth of acidophilic lactobacilli, and the effect of promoting the growth of acidophilic lactobacilli can be more favorably exhibited at a relatively high concentration of LAB-EV. In other words, it was confirmed that the effect of LAB-EV in promoting the growth of acidophilic lactobacilli is dose-dependent. For example, when the particle number concentration is 10 10 When co-cultivating LAB-EVs at particles / mL with acidophilic lactobacilli, the growth of acidophilic lactobacilli can be significantly increased, and the particle number concentration is 10 8 When co-cultured with acidophilic lactobacilli at 1 / ml LAB-EVs, the effect of promoting the growth of acidophilic lactobacilli was secondary. EXAMPLES

[0049] <Example 4: Co-culture of the extracellular vesicles of Pediococcus acidilactici of the present invention with intestinal bacteria> In this example, LAB-EV was co-cultured with the intestinal bacteria Lachnospiraceae sp. and Ruminococcaceae sp., respectively, and then the absorbance value at a wavelength of 600 nm was measured at different time points, and finally, the line graphs shown in Figures 4A and 4C were obtained, respectively. The plate count method was used to calculate the bacterial count (Log CFU / mL) at different time points, and finally, the bar graphs shown in Figures 4B and 4D were obtained, respectively. Among them, the data from three repeated runs are expressed as the mean (Mean) ± standard error (SEM), and significant differences (p<0.05) are represented by different English alphabets.

[0050] As can be seen from the results shown in Figures 4A, 4B, 4C, and 4D, LAB-EV had no effect on the growth of the enterobacteria Lachnospira and Ruminococcus, and furthermore, neither relatively high nor relatively low concentrations of LAB-EV had any effect on the growth of the enterobacteria Lachnospira and Ruminococcus. EXAMPLES

[0051] <Example 5: Fluorescent staining by reaction of LAB-EV with mouse fecal microorganisms> In order to clarify whether intestinal microorganisms ingest LAB-EVs and to examine the types of intestinal bacteria that can ingest LAB-EVs, in this example, 10 8 Particles / ml of LAB-EVs (green), whereas mouse fecal bacteria were stained with DRAQ5 (red) and then added to the microwell plate, of which CFSE has an excitation wavelength of 492 nm, an emission wavelength of 517 nm, and DRAQ5 has an excitation wavelength of 647 nm, an emission wavelength of 665 nm, CFSE is carboxyfluorescein succinimidyl ester staining reagent, and DRAQ5 was purchased from Abcam (Bristol, UK).

[0052] Referring to the results shown in Figure 5, red fluorescence marks bacterial cells in mouse feces stained with DRAQ5, and the cells have a rod-shaped or spherical distribution, and green fluorescence marks LAB-EVs stained with CFSE, and the polymerization area of ​​both is marked with yellow. As shown by the test results, LAB-EVs are taken into the cells by intestinal microorganisms, and intestinal microorganisms are composed of many kinds of bacteria, and some bacterial positions may not be polymerized with green fluorescence, which indicates that not all kinds of bacteria necessarily take in LAB-EVs, but only certain bacterial groups take in extracellular vesicles. EXAMPLES

[0053] Example 6: Possibility of LAB-EV being taken up by mouse intestinal bacteria In this example, the intestinal microorganisms of mice without LAB-EV (FIG. 6A) and mice with LAB-EV (FIG. 6B) were sent to a flow cell sorter and analyzed. Among them, the intestinal microorganisms of mice with LAB-EV were those with a particle count of 10 10 LAB-EVs were stained with CFSE and reacted with mouse intestinal bacteria (n=6) in an anaerobic environment at 37°C. CFSE is carboxyfluorescein succinimidyl ester staining reagent.

[0054] Referring to the results shown in Figure 6A, the intestinal microorganisms of mice without LAB-EV were sent to a flow cell sorter for analysis, and then the bacterial groups were selected and analyzed in this specific region. The selection range included cells of 1 μm, 2 μm, and 10 μm in size, and it was found that the majority of the intestinal microorganisms in the quadrant diagram were in the R8 quadrant, accounting for approximately 98.58% of the total bacterial groups.

[0055] Referring to the results shown in FIG. 6B, the intestinal microorganisms of the mice with LAB-EV were sent to a flow cell sorter for analysis, and the range of the bacterial population was selected, which also included cells of 1 μm, 2 μm, and 10 μm in size, and in the quadrant diagram, the majority of the cells were R8. Besides falling into the quadrants, we found that 32.31% of cells fell within the R9 quadrant.

[0056] From the above results, it was found that the cell sizes in the selected range were 1 μm, 2 μm, and 10 μm, and that these lengths corresponded to the size of the bacteria. By analyzing the intestinal microorganisms of mice that had not been treated with LAB-EVs as a control group, it was possible to determine the range of the mouse intestinal bacterial community. Furthermore, a fluorescent reaction was observed in the intestinal microorganisms that had been treated with fluorescently stained LAB-EVs, indicating that some microorganisms in the mouse intestine ingest LAB-EVs, and that approximately 32.31% of the bacteria in the mouse intestine ingest LAB-EVs. EXAMPLES

[0057] Example 7: Elucidation of the types of intestinal microorganisms in mice ingesting LAB-EVs In this example, the intestinal microorganisms that ingest the LAB-EVs in Example 6 are extracted and separated, and then sequenced. Referring to the results shown in Figure 7, after the intestinal microorganisms that react with the LAB-EVs are sequenced, it is found that the multiple intestinal microorganisms include a total of 1 kingdom, 9 phyla, 14 classes, 19 orders, 37 families, 74 genera, and 87 species. The relative abundance bar graph in Figure 7 shows the percentage of bacteria from different taxonomic groups, all of which are eubacteria, with the majority being from the phyla Firmicutes and Bacteroidetes, accounting for approximately 49% and 47%, respectively. In terms of the classes of bacteria, the breakdown is as follows: Bacteroidia at 47%, Clostridia at 44%, and Bacilli at 4%. In terms of families, the Lachnospiraceae family is the most abundant, accounting for 33%. In terms of genera and species, Muribaculum / Muribaculum sp. and Lachnospira / Lachnospira sp. are the top two with 22% and 19%, respectively.

[0058] For easy comparison, the relative abundance bar graph of FIG. 7 includes various microorganisms from the following classes in order: Kingdom Bacteria; Phylum Proteobacteria, Bacteroidetes, and Firmicutes; Class Bacilli, Clostridia, and Bacteroidia; Order Lactobacillales, Order Clostridiales, and Order Clostridiales. ostridiales and Bacteroidales, with the families Lactobacillaceae, Bacteroidaceae, Rikenellaceae, Ruminococcaceae, Prevotellaceae and Lachnospiraceae, with the genera Alloprevotella, Rikenella, Butyricicoccus, (ASF356 sp.), Ruminiclostridium sp., Alistipes sp., Lachnoclostridium sp., Roseburia sp., Lactobacillus sp., Bacteroides sp., Prevotella sp., Lachnospira sp. and Muribaculaceae sp., and Alloprevotella sp., Rikenellaceae sp., Butyricicoccus sp., Spore-forming Clostridia (ASF356 sp.), Ruminiclostridium sp., Lactobacillus sp., Alistipes sp. sp.), Lachnoclostridium sp., Roseburia sp., Bacteroides sp.), Prevotella sp., Lachnospiraceae sp. and Muribaculaceae sp. .

[0059] In addition, in the above-mentioned several examples, the co-culture of LAB-EVs with acidophilic lactobacilli and the fluorescent staining test of LAB-EVs with intestinal microorganisms showed that LAB-EVs were consumed by a specific group of microorganisms, and the flow cell sorter experiment also found that approximately 32.31% of intestinal microorganisms utilize LAB-EVs. At the same time, further sequencing also found that the two genera Muribaculaceae and Lachnospiraceae were the most abundant among the microorganisms that consumed LAB-EVs, accounting for 22% and 19%, respectively. EXAMPLES

[0060] <Example 8: Identification and differentiation of the novel Pediococcus acidilactici strain of the present invention> In this example, the complete genome sequence of the Pediococcus acidilactici of the present invention is analyzed using the next-generation MiSeq (Illumina, Inc., USA) and the next-generation MinION (Oxford Nanopore Technologies, Inc., UK) sequencer platforms, and the differences are found by comparing with genome databases (e.g., GenBank, Ensembl, BioCyc, RefSeq, etc.). The identity of the Pediococcus acidilactici of the present invention with 27 genomes that completely assemble the same species as the Pediococcus acidilactici species registered in GenBank was analyzed. As shown in Table 1 below, it calculates the average nucleotide identity (ANI) with the Pediococcus acidilactici of the present invention using FastANI v1.33. Thus, Fig. 8 shows a phylogenetic tree calculated and drawn using Roary v 3.11.2 and FastTree 2.1, which represents the genetic relationship between different strains of Pediococcus acidilactici. Pediococcus acidilactici PB22 is the most similar strain (ANI: 99.16%) to the Pediococcus acidilactici of the present invention, and no Pediococcus acidilactici strain having a genome completely homologous to the Pediococcus acidilactici of the present invention has been found.

[0061] [Table 1]

[0062] Next, in order to effectively identify and distinguish the DNA sequence of the Pediococcus acidilactici of the present invention, this embodiment distinguishes between different strains of the same species of Pediococcus acidilactici by designing primers that can identify genomic mutation regions, and the multiple primers are summarized in Table 2 below. Table 3 shows the primer combination scheme and the amplified sequence of the target strain. After comparison with the RefSeq database (the database includes the complete genome, scaffold sequences and contig sequences), the amplified sequence of the primer combination CGPA01_1590-F / R for identifying Pediococcus acidilactici of the present invention has the same fragment only in the MA18 / 5M genome of Pediococcus acidilactici, while the amplified sequence of the primer combination MA18 / 5M_850-F / R has the fragment only in MA18 / 5M of Pediococcus acidilactici, and this fragment does not exist in the genome of Pediococcus acidilactici of the present invention.

[0063] [Table 2]

[0064] [Table 3]

[0065] Next, polymerase chain reaction (PCR) was performed using the primer combinations in Table 2 above. The total reaction volume of the PCR was 20 μl, containing 0.1 ng of strain DNA, 500 nM of primers, and 10 μl of Taq DNA Polymerase Master Mix RED (Ampliqon A / S, DK). The PCR reaction conditions were heating at 95°C for 2 minutes (2 min), heating again at 95°C for 20 seconds (20 sec), binding at 60°C for 30 seconds (30 sec), and elongation at 72°C for 30 seconds (30 sec), and this cycle was repeated 30 times under these conditions. Finally, elongation was performed at 72°C for 5 minutes (5 min). After completing the PCR reaction, the PCR product can be extracted and electrophoresis is performed for 40 minutes at a voltage of 100V using 1.8% agarose gel in 1XTAE buffer solution. The electrophoretic gel sheet is then stained with SYBR Safe staining reagent (Thermo Fisher Scientific, USA). The stained electrophoretic gel sheet is placed in a blue light (470 nm) light box for observation, and an image is captured and saved in a file.

[0066] Table 4 shows the strains for confirming the unique sequence of the Pediococcus acidilactici strain of the present invention. Except for the Pediococcus acidilactici of the present invention and MA18 / 5M, all the strains listed in Table 4 were purchased from Bioresource Collection and Research Center, Food Industry Research and Development Institute, Hsinchu, Taiwan, and all of the strains belong to the genus Pediococcus, including Pediococcus pentosaceus, Pediococcus parvulus, and the same species of Pediococcus acidilactici. Pediococcus acidilactici MA18 / 5M (also known as R1001) was isolated from Jarro-Dophilus EPS (Jarrow Formulas, Inc.) products.

[0067] [Table 4]

[0068] Please refer to Figure 9, which is an electrophoretic diagram after PCR reaction of CGPA01_1590-F / R primer and Pediococcus sp. strain DNA. As shown in Figure 9, only Pediococcus acidilactici of the present invention and MA18 / 5M show a bright band at 115bp. Please refer to Figure 10, which is an electrophoretic diagram after PCR reaction of DNA of Pediococcus acidilactici strain and MA18 / 5M of the present invention obtained by amplification using MA18 / 5M_850-F / R primer. As shown in Figure 10, only Pediococcus acidilactici strain MA18 / 5M shows a bright band at 505bp.

[0069] In summary, genome analysis shows the differences between the Pediococcus acidilactici of the present invention and the Pediococcus acidilactici strains, among which the Pediococcus acidilactici of the present invention has the highest identity with the PB22 genome. PCR and specific primers were used to distinguish the Pediococcus acidilactici of the present invention from other publicly available Pediococcus strains, and the primer combinations were CGPA01_1590-F / R and MA18 / 5M_850-F / R, respectively. CGPA01_1590-F / R only amplifies the Pediococcus acidilactici of the present invention and MA18 / 5M, but does not amplify other Pediococcus strains. For this reason, it is necessary to use it together with the MA18 / 5M_850-F / R primer, which further distinguishes the Pediococcus acidilactici of the present invention from MA18 / 5M. In the Pediococcus acidilactici of the present invention, only the CGPA01_1590-F / R primer amplification bright zone appears, and in the Pediococcus acidilactici MA18 / 5M, the CGPA01_1590-F / R primer and the MA18 / 5M_850-F / R primer amplification bright zone appears. In addition, as can be seen from the above genome analysis and PCR results, the Pediococcus acidilactici SWP-CGPA01 provided by the present invention is a novel lactic acid bacteria isolate.

[0070] As described above, the novel lactic acid bacteria of the present invention, the composition for improving the intestinal microbial species composition, and the products and uses of said lactic acid bacteria have been fully and clearly described. It should be emphasized that the above detailed description is a specific description of the possible embodiments of the present invention, and the scope of the present invention is not limited to these embodiments, and the equivalent effects or modifications thereof are still included in the scope of the claims of the present application as long as they do not deviate from the technical spirit of the present invention.

[0071] The Pediococcus acidilactici of the present invention has been deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) of the United Kingdom on January 12, 2023 (date of deposit), and its accession number is NCIMB 44102.

Claims

1. A lactic acid bacterium, characterized in that it is Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

2. A composition for improving intestinal microbial species composition, comprising an effective amount of extracellular vesicles, the extracellular vesicles being capable of being secreted from lactic acid bacteria, and the lactic acid bacteria being Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

3. The effective amount is a particle number concentration of at least 10 8 The composition of claim 2, characterized in that the extracellular vesicles are present in an amount of 100 / ml.

4. The composition according to claim 2, wherein the extracellular vesicles are any one selected from the group consisting of exosomes, microvesicles, ectosomes, and apoptotic bodies.

5. The composition according to claim 2, characterized in that it has the ability to improve the gut microbial species composition, which can affect the clinical course of Alzheimer's disease (AD).

6. The composition of claim 2, wherein the extracellular vesicles are capable of influencing the growth of Firmicutes and / or Bacteroidetes.

7. The composition of claim 2, wherein the extracellular vesicles are capable of influencing the growth of at least one bacterial class, and the bacterial class is at least one selected from the group consisting of Bacteroidia, Clostridia, and Bacilli.

8. The extracellular vesicles are capable of influencing the growth of at least one bacterial family, and the bacterial family includes Lactobacillaceae, Muribaculaceae, Lachnospiraceae, Clostridiaceae, Desulfovibrioaceae, Erythrocytes, and the like. The composition according to claim 2, characterized in that it is at least one selected from the group consisting of Erysipelotrichaceae, Eggerthellaceae, Ackermansiaceae, Ruminococcusceae and Eubacteriaceae.

9. The composition according to claim 2, characterized in that the extracellular vesicles are capable of influencing the growth of Muribaculum and / or Lachnospira.

10. The composition according to claim 2, wherein the extracellular vesicles are capable of promoting the growth of Lactobacillus acidophilus.

11. A nutritional supplement comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

12. A food product comprising Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

13. A dietary supplement comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

14. A food additive comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

15. A pharmaceutical composition comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

16. A feed comprising Pediococcus acidilactici deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

17. A use of lactic acid bacteria for preparing a composition for improving intestinal microbial species composition, characterized in that the lactic acid bacteria is Pediococcus acidilactici deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.

Citation Information

Patent Citations

  • Bifidobacterium sp. strain, or pediococcus sp. strain, and vesicles derived therefrom, and Anti-inflammatory and antibacterial uses thereof

    WO2023014048A1